Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,512.38 -3.89 -0.03%
TOPIX 1,171.40 -1.97 -0.17%
HANG SENG 22,760.24 64.23 0.28%

Investments on New Facilities, Marketing Grants, Commercial Releases, and Trial Results - Research Report on AstraZeneca,



  Investments on New Facilities, Marketing Grants, Commercial Releases, and
Trial Results - Research Report on AstraZeneca, Theravance, Accuray, Volcano,
                                 and Auxilium

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, November 21, 2013

NEW YORK, November 21, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting
AstraZeneca plc (NYSE: AZN), Theravance, Inc. (NASDAQ: THRX), Accuray, Inc.
(NASDAQ: ARAY), Volcano Corporation (NASDAQ: VOLC), and Auxilium
Pharmaceuticals, Inc. (NASDAQ: AUXL). Today's readers may access these reports
free of charge - including full price targets, industry analysis and analyst
ratings - via the links below.

AstraZeneca plc Research Report

On November 11, 2013, AstraZeneca plc (AstraZeneca) announced that it intends
to invest £120 million ($190 million) in a new facility at its global
manufacturing site in Macclesfield, UK to continue production of Zoladex, an
injectable treatment for prostate cancer. The Company stated that this
investment secures 300 existing Zoladex jobs at the site and will create over
200 temporary jobs during the construction and commissioning phase until early
2017. David Smith, Executive Vice President of Operations at AstraZeneca
stated, "Zoladex is one of AstraZeneca's leading cancer drugs, supplied to
patients across the globe. This new facility will support the continued
production of this important medicine in the UK." According to the Company,
the construction of the new facility will begin in 2013 and will be due for
completion in 2016. In addition, AstraZeneca stated that the products
manufactured in the new facility will begin to be supplied to markets in 2017.
The Full Research Report on AstraZeneca plc - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at:

http://www.analystscorner.com/r/full_research_report/09cc_AZN

--

Theravance, Inc. Research Report

On November 18, 2013, Theravance, Inc. (Theravance), together with GSK,
announced that the European Commission has granted marketing authorization for
RELVAR® ELLIPTA®, now licensed across 31 European countries for asthma and
COPD. Darrell Baker, Senior Vice President and Head of GSK Global Respiratory
stated, "We are delighted that Relvar Ellipta is now licensed, which means
that healthcare professionals across Europe will have the option to prescribe
an ICS/LABA that offers 24-hour efficacy from a once-daily dose, delivered in
our new Ellipta inhaler." Rick E Winningham, CEO of Theravance, added, "We are
delighted that another significant regulatory body has granted marketing
authorisation for Relvar Ellipta for the treatment of asthma and COPD and look
forward to seeing the benefits of this effective once-daily treatment option
in these patient populations." The Full Research Report on Theravance, Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/fa70_THRX

--

Accuray, Inc. Research Report

On November 18, 2013, Accuray, Inc. (Accuray) announced that its management
will present at the Piper Jaffray 25^th Annual Healthcare Conference in New
York on December 4, 2013 at 1:00 p.m. EST / 10:00 a.m. PST. The Company added
that a live webcast of the presentation will be available online via the
Investor Relations page of the Company website. Accuray further stated that a
webcast replay of the presentation can be accessed approximately one hour
after the live presentation concludes and will be available for about 30 days
following the event. The Full Research Report on Accuray, Inc. - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://www.analystscorner.com/r/full_research_report/36bf_ARAY

--

Volcano Corporation Research Report

On November 13, 2013, Volcano Corporation (Volcano) announced the commercial
release and initial implantations of its Crux® Vena Cava Filter (VCF) in
patients at risk for recurrent pulmonary embolism (PE). The Company stated
that it is the only filter with a double helical design that self-centers to
help prevent filter tilt and offers the Bi-Trieval™ option of retrieval via
either the jugular or femoral vein. Thomas Fogarty, M.D., Founder of Crux
Biomedical (which developed the Crux VCF and was acquired by Volcano in 2012)
stated, "The Crux VCF represents the first major design innovation for IVC
filters in decades. Its unique self-centering design addresses the risks of
migration and tilt, provides filtration across the entire lumen of the vessel,
and provides for the Bi-Trieval™ option of either femoral or jugular
retrieval." Neil Hattangadi, M.D., Vice President and General Manager of
Volcano's Peripheral Vascular Business Unit added, "This milestone represents
one of many recent developments at Volcano that demonstrates the company's
commitment to expanding our peripheral product offering and building on our
heritage in diagnostics to deliver new therapeutic solutions for the patients
and physicians we serve." The Full Research Report on Volcano Corporation -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/14bf_VOLC

--

Auxilium Pharmaceuticals, Inc. Research Report

On November 18, 2013, Auxilium Pharmaceuticals, Inc. (Auxilium) announced the
results of the MULTICORD study, an open-label, Phase 3b study of the treatment
of multiple joints injected concurrently. According to the Company, the study
revealed that two concurrent injections of XIAFLEX® in patients with multiple
Dupuytren's contractures resulted in an improvement in joint contracture and
range of motion, compared to those seen in previous studies when XIAFLEX was
administered as single injections, 30 days apart. Auxilium stated that the
results of the trial and the earlier MULTICORD studies support Auxilium's
planned supplemental Biologics License Application (sBLA) submission to the
U.S. Food and Drug Administration (FDA) in Q1 2014, in order to expand the
labeling for the concurrent treatment of multiple palpable cords. The Full
Research Report on Auxilium Pharmaceuticals, Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at:

http://www.analystscorner.com/r/full_research_report/86a4_AUXL

----

EDITOR NOTES:

 1. This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
 2. Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we
    are only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
 3. This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
 4. If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
 5. For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
 6. Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Namrata Maheshwari,
CFA, has only reviewed the information provided by Equity News Network in this
article or report according to the Procedures outlined by Equity News Network.
Equity News Network is not entitled to veto or interfere in the application of
such procedures by the outsourced provider to the articles, documents or
reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

AnalystsCorner.com

SOURCE Analysts' Corner

Contact: Joe Thomas; +1-310-496-8071 (North America)
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement